SaneCite
Lists

Who keeps citing retracted work?

The retracted papers still cited most often as support, and the journals and authors whose papers do it most. How each list was checked, and replies from the people named. Every entry is an AI reading, rung 2 on our severity scale, pending human review. Census data as of 14 Oct 2026; corrections through 9 Nov 2026.

Retracted papers

The retracted papers most often still cited as support.

Ranked by how many citations, made after the retraction, use the paper as support for a claim.

Together, these 10 papers are cited as support by 482 papers published after their retraction, among them 13 systematic reviews or meta-analyses and 13 trials; 164 of those acknowledge grants. In turn, 14,916 later papers cite those 482, among them 466 systematic reviews or meta-analyses, 249 trials and 7 guidelines. This measures reach, not harm. Each paper below says what it claimed, why its retraction matters and what it reached.

The retracted papers most often still cited as support, ranked
#Retracted paperCited as support after retractionSecond reading
1Visfatin: a protein secreted by visceral fat that mimics the effects of insulinFukuhara A et al., Science 2004. Retracted 2007: An Osaka University research integrity committee examined the insulin-receptor experiments and the university recommended retraction; the authors "continue to stand by our conclusions" but found "not all preparations of visfatin bind to and activate the insulin receptor".
What it claimed
Belly fat releases a hormone, visfatin, that acts like insulin and lowers blood sugar, a possible new route to treating diabetes.
Why it matters
The insulin-like effect was the headline, and the notice says not every preparation of visfatin acts on the insulin receptor. Reviews of obesity and diabetes still cite the paper as support.
What it reached after the retraction
  • Cited as support by 104 papers, among them 2 systematic reviews or meta-analyses, 44 reviews and 2 trials.
  • Grants 34 of those papers acknowledge grants from 46 funders, most often National Natural Science Foundation of China (6), National Science Centre, Poland (4) and Instituto de Salud Carlos III (3).
  • In turn 4,430 later papers cite those papers, among them 141 systematic reviews or meta-analyses, 116 trials and 1 guideline.
  • Followed by reading The most-cited of them is a 2014 review that repeats the insulin-like claim and cites the retracted paper for it (cited 1,301 times since). 67 later papers cite it and mention visfatin; we could read 56 of them in full. 7 cite it about visfatin, and none of them repeats the insulin-like claim: they name visfatin among the inflammatory hormones fat tissue releases.
paper · retraction notice · every citation
104of 314 judged (33.1%)9 of 14its findings
2Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19Mehra MR et al., N Engl J Med 2020. Retracted 2020: The authors could not get the raw data audited, so they were "unable to validate the primary data sources".
What it claimed
In records from 8,910 hospital patients with Covid-19, heart disease raised the risk of dying, but common blood-pressure drugs (ACE inhibitors and ARBs) did not.
Why it matters
It spoke to whether patients with Covid-19 should keep taking these drugs. Its data came from a database no one could check, yet later papers still cite it as support.
What it reached after the retraction
  • Cited as support by 80 papers, among them 8 systematic reviews or meta-analyses and 26 reviews.
  • Grants 23 of those papers acknowledge grants from 44 funders, most often National Institute for Health Research (NIHR) (3) and US National Institutes of Health (2).
  • In turn 2,463 later papers cite those papers, among them 116 systematic reviews or meta-analyses, 22 trials and 5 guidelines.
  • What we checked We read the three of those guidelines that are free to read: each cites those papers for other points, such as heart disease raising the risk from Covid-19, not for the retracted finding on blood-pressure drugs.
  • Followed by reading The second most-cited of them is a 2021 review that repeats, with its numbers, the retracted paper's finding that ACE inhibitors and ARBs did not change the risk of dying (cited 166 times since). 120 later papers cite it and mention angiotensin; we could read 88 of them in full. 19 cite it about angiotensin, and none of them repeats that finding: they cite it for how the virus uses the ACE2 receptor to drive inflammation, not for the drug finding.
paper · retraction notice · every citation
80of 365 judged (21.9%)9 of 12its findings
3Predictive validity of a medication adherence measure in an outpatient settingMorisky DE et al., J Clin Hypertens (Greenwich) 2008. Retracted 2023: An independent statistical review found the results "misleading due to issues regarding the sensitivity and specificity" of the adherence measure.Most citations use the MMAS-8 adherence questionnaire and its cut-offs.
What it claimed
An eight-question survey shows which patients with high blood pressure skip their medicines; a score below 6 flags poor blood-pressure control.
Why it matters
The survey and its cut-off are widely used to measure whether patients take their medicines, including in trials. Papers that cite this paper as support use accuracy figures the journal now calls misleading.
What it reached after the retraction
  • Cited as support by 56 papers, among them 1 systematic review or meta-analysis, 2 reviews and 7 trials.
  • Grants 18 of those papers acknowledge grants from 34 funders, most often US National Institutes of Health (2).
  • Registered trials 3 trials registered on ClinicalTrials.gov after the retraction list it among their references, enrolling or planning 1,230 people.
  • In turn 225 later papers cite those papers, among them 16 systematic reviews or meta-analyses and 7 trials.
  • What we checked All three of those registered trials use the MMAS-8 survey itself to measure their results (ClinicalTrials.gov NCT06068309, NCT06117722 and NCT07145983).
paper · retraction notice · every citation
56of 183 judged (30.6%)11 of 14its questionnaire
4Association Between Physician Burnout and Patient Safety, Professionalism, and Patient Satisfaction: A Systematic Review and Meta-analysisPanagioti M et al., JAMA Intern Med 2018. Retracted 2020: A University of Manchester panel "found no evidence of intentional fabrication" but, because of flaws in the review process, "cannot confirm that the results of the meta-analysis are wholly valid".
What it claimed
Pooling 47 studies of 42,473 doctors, burnout was linked to more patient-safety incidents, less professional care and less satisfied patients.
Why it matters
Its figures are used to argue that doctor burnout harms patients. The investigating panel could not confirm they are valid.
What it reached after the retraction
  • Cited as support by 53 papers, among them 1 systematic review or meta-analysis, 6 reviews and 1 trial.
  • Grants 15 of those papers acknowledge grants from 19 funders, most often US Department of Veterans Affairs (2) and US National Institutes of Health (2).
  • Registered trials 3 trials registered on ClinicalTrials.gov after the retraction list it among their references, enrolling or planning 349 people.
  • In turn 501 later papers cite those papers, among them 32 systematic reviews or meta-analyses and 10 trials.
  • What we checked All three registered trials test programmes to reduce burnout in health workers and cite the paper in their background.
  • Followed by reading The most-cited of them is a 2021 review that repeats the link between doctor burnout and harm to patients, with the retracted paper among its sources (cited 52 times since). 51 later papers cite it and mention burnout; we could read 37 of them in full. 25 cite it about burnout, and 15 of them repeat that link, though the review itself found a clear link in only 4 of the studies it covered, against 6 that found none.
paper · retraction notice · every citation
53of 203 judged (26.1%)11 of 13its findings
5The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytesXu C et al., J Cell Sci 2007. Retracted 2011: The authors retracted it over "the misuse and re-use of western blot bands" in Figures 3 and 4A, which broke the journal's editorial policy.
What it claimed
Two small RNA molecules in heart muscle push stressed heart cells in opposite directions: miR-1 toward death, miR-133 toward survival.
Why it matters
The paper is cited as a building block in research on heart attacks and heart failure; the figures behind it were withdrawn.
What it reached after the retraction
  • Cited as support by 51 papers, among them 19 reviews.
  • Grants 15 of those papers acknowledge grants from 40 funders, most often US National Institutes of Health (6), National Natural Science Foundation of China (4) and British Heart Foundation (2).
  • In turn 2,003 later papers cite those papers, among them 31 systematic reviews or meta-analyses and 10 trials.
  • Followed by reading The most-cited of them is a 2017 study that repeats the claim that miR-133 protects heart cells from dying, citing the retracted paper (cited 145 times since). 69 later papers cite it and mention miR-133; we could read 63 of them in full. 43 cite it about miR-133, and 1 of them repeats that claim: the others cite the study for its own results, on stem cells engineered to carry miR-133.
paper · retraction notice · every citation
51of 98 judged (52.0%)11 of 14its findings
6Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during agingWenz T et al., Proc Natl Acad Sci U S A 2009. Retracted 2016: A University of Cologne investigation "concluded that there was scientific misconduct": blots in Figs. 2D and 3B also appear in an unrelated paper, and a tubulin blot is duplicated.
What it claimed
Raising a muscle protein, PGC-1alpha, protected ageing mice from muscle loss and metabolic disease.
Why it matters
It is cited in research on age-related muscle loss (sarcopenia), but a university investigation found misconduct in its figures.
What it reached after the retraction
  • Cited as support by 31 papers, among them 1 systematic review or meta-analysis, 15 reviews and 1 trial.
  • Grants 14 of those papers acknowledge grants from 20 funders, most often Japan Society for the Promotion of Science (3) and US National Institutes of Health (3).
  • In turn 1,288 later papers cite those papers, among them 45 systematic reviews or meta-analyses and 36 trials.
paper · retraction notice · every citation
31of 60 judged (51.7%)13 of 13its findings
7circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 familyChen L et al., Oncogene 2017. Retracted 2019: The authors found "serious errors in Figs. 5c and 7b, resulting from the data collection process" and are no longer confident in the conclusions.
What it claimed
A circular RNA, circRNA_100290, helps mouth-cancer cells grow by soaking up miR-29 molecules, which made it a possible treatment target.
Why it matters
Later cancer studies cite the mechanism as support; its own authors withdrew it.
What it reached after the retraction
  • Cited as support by 30 papers, among them 6 reviews.
  • Grants 12 of those papers acknowledge grants from 13 funders, most often National Natural Science Foundation of China (6).
  • In turn 519 later papers cite those papers, among them 4 systematic reviews or meta-analyses.
paper · retraction notice · every citation
30of 94 judged (31.9%)9 of 13its findings
8Spontaneous human adult stem cell transformationRubio D et al., Cancer Res 2005. Retracted 2010: The authors could not reproduce some of the reported transformation events and "suspect the phenomenon is due to a cross-contamination artifact"; five of the seven authors agreed to the retraction.
What it claimed
Human adult stem cells of the kind used in cell therapies can turn cancerous on their own after months in the lab.
Why it matters
It bears on the safety of stem-cell therapies and is cited in reviews of them. Its authors now suspect the cancer came from contaminated cultures.
What it reached after the retraction
  • Cited as support by 26 papers, among them 14 reviews and 1 trial.
  • Grants 9 of those papers acknowledge grants from 15 funders, most often National Natural Science Foundation of China (3) and US National Institutes of Health (2).
  • Registered trials 2 trials registered on ClinicalTrials.gov after the retraction list it among their references, enrolling or planning 90 people.
  • In turn 1,509 later papers cite those papers, among them 26 systematic reviews or meta-analyses and 9 trials.
  • What we checked Both registered trials test stem-cell treatments in patients, for traumatic brain injury and for diabetic foot ulcers, and cite the paper in their background.
  • Followed by reading The most-cited of them is a 2012 review of clinical uses of these stem cells that repeats the finding that they can turn cancerous in culture, citing the retracted paper (cited 326 times since). 42 later papers cite it and mention cell transformation; we could read 31 of them in full. 2 cite it about cell transformation, and 1 of them repeats that finding: the other says most researchers think these cells do not turn cancerous in culture.
paper · retraction notice · every citation
Reply from the senior author, received 22 Oct 2026Dr Bernad says the 2005 paper was the first report of an apparent spontaneous transformation of mesenchymal stem cells in culture, at a time when these cells were being tested in many cell therapies, so it had a large impact on the field. Soon after publication his group found that the main conclusion could not be reproduced and was most probably due to a very small number of contaminating transformed cells that overgrew the cultures. He says the group contacted Cancer Research to offer a retraction; the journal preferred a short notice (de la Fuente et al., 2010) to the longer one they wrote. He says the group approached the journal soon after finding the result could not be reproduced. He did not give the date of that contact by 28 October (the notice was published in August 2010). He proposed a note for later authors, printed below as he wrote it, and points to his group's later work on long-term culture of these cells.Soon after publication (Rubio et al., 2005) we realized that the main conclusion was non reproducible and that the putative spontaneous transformation was most probably due to a highly minoritarian number of a transformed cell line.Statement from the senior author, printed as written:

Please, be aware that the main conclusion of the manuscript (Rubio et al., 2005) was non-reproducible and that the putative spontaneous transformation of MSC, upon in vitro culture, was most probably due to a highly minoritarian number of contaminant- transformed cells, that with time overgrow the cultures. Then it was retracted (de la Fuente et al., 2010). Therefore, continue citing this work as a proof of the potential of MSC to be transformed upon prolonged in vitro culture, is no appropriate and can induce more confusion to the field

Our response: The retraction notice was published in Cancer Research in August 2010 (doi:10.1158/0008-5472.CAN-10-2451). His group's later papers: Estrada JC et al., Cell Death Dis 2013 (replicative senescence of these cells in long-term culture is closely linked to aneuploidy) and Sepúlveda JC et al., Stem Cells 2014 (senescence abrogates their therapeutic potential in a mouse model of lethal endotoxemia). The entry stands: the citations counted were made after the retraction and use the paper as support.Changes since our letter:
  • Reason changed from the Retraction Watch group "error or unreliable results" to the notice's wording: the authors could not reproduce some of the transformation events and suspect a cross-contamination artifact; five of the seven authors agreed to the retraction.
  • Citations judged: from 135 in our letter to 134. One citing paper, which only mentions the work in passing, was published online on 13 July 2010, before the retraction, and is left out; the 33 citations that use it as support are unchanged.
  • 23 Oct 2026: a check of the citing papers' full text found 3 of the 33 citations in our letter were not cited as support (two warn readers about the retraction, one credits the paper with something it does not report). A full-text check of the other 30 the same day kept 26: two more warn readers and two more credit the paper with something it does not report. Because every paper near the last places was read in full, the paper stays on the list, at place 8 with 26. The three that credit the paper with something it does not report leave the judged base, so 131 citations are judged now: 26 of 131 cite it as support.
26of 131 judged (19.8%)each one read twice12 of 14its findings
8A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cellsHattori Y et al., Diabetologia 2010. Retracted 2011: Retracted "following the discovery of redundant publication": part of Figure 2c had been published before in Cardiovascular Research.
What it claimed
Liraglutide, a diabetes drug, raised nitric oxide and calmed inflammation in cells that line blood vessels, a possible way it protects the heart and arteries.
Why it matters
Liraglutide is widely prescribed for diabetes and weight loss, and papers on its heart benefits cite this lab result as part of the explanation. The journal retracted it because part of a figure had been published before in another journal.
What it reached after the retraction
  • Cited as support by 26 papers, among them 14 reviews and 1 trial.
  • Grants 9 of those papers acknowledge grants from 15 funders, most often National Natural Science Foundation of China (4).
  • In turn 1,493 later papers cite those papers, among them 49 systematic reviews or meta-analyses, 37 trials and 1 guideline.
paper · retraction notice · every citation
26of 54 judged (48.1%)each one read twice0 of 0its findings
10Selective killing of cancer cells by a small molecule targeting the stress response to ROSRaj L et al., Nature 2011. Retracted 2018: Problems with Fig. 1d and Supplementary Fig. 31b, and missing original data, "raise concerns regarding the integrity of the figures"; five authors disagree with the retraction.
What it claimed
A natural compound, piperlongumine, kills cancer cells but spares normal ones, and shrank tumours in mice.
Why it matters
Killing only cancer cells made it a lead for cancer drugs. The journal found problems with key figures and missing original data.
What it reached after the retraction
  • Cited as support by 25 papers, among them 7 reviews.
  • Grants 15 of those papers acknowledge grants from 18 funders, most often National Natural Science Foundation of China (6) and US National Institutes of Health (2).
  • In turn 543 later papers cite those papers, among them 7 systematic reviews or meta-analyses and 2 trials.
paper · retraction notice · every citation
25of 93 judged (26.9%)each one read twice13 of 15its findings

Second reading: of up to 15 citations drawn at random and read again (fewer where a later full-text check took one out of scope), how many cite the paper as support, and what they use it for. The sample was drawn before the full read; where the full read changed a citation's label, the final label is the one counted here and in second-reading.csv. Ties share a place. Each reason quotes or closely follows the retraction notice; where we have not yet read a notice, we say so.

Every paper on this list, and each paper near the last place, was read in full on 23 October: each citation counted as "cited as support" was checked against the citing paper's full text, and those that turned out to be passing mentions, warnings about the retraction, citations of the retraction notice or of something else, or that credit the paper with something it does not report, no longer count. For the papers at and just below the last places, each citation was read twice, independently, and a third reading settled the 11 on which the first two disagreed. These are AI readings. The papers left off after reading were judged on their second reading, not read in full.

Left off after reading

These papers would make the list on the count alone, but reading them showed the citations cite something the retraction does not touch, for example a tool or method in the paper that still works.

Retracted papers left off after reading, with the reason
Retracted paperSupportWhy it is left off
An enhanced transient expression system in plants based on suppression of gene silencing by the p19 protein of tomato bushy stunt virusVoinnet O et al., Plant J 2003. Retracted 2015: Image duplications in Figure 3b and in loading-control lanes of Figures 2g, 3a, 4e and 4f; the authors "accept that integrity of the scientific literature is compromised by the data manipulation".paper · retraction notice · every citation167of 246Citations use the p19 lab tool the paper describes, which still works (14 of 15 read). It was retracted over duplicated figures.
Global Increase in Breast Cancer Incidence: Risk Factors and Preventive MeasuresKashyap D et al., Biomed Res Int 2022. Retracted 2023: The publisher found "evidence of systematic manipulation of the publication and peer-review process" and cannot "vouch for the reliability or integrity" of the article.paper · retraction notice · every citation29of 143A review: citations use its summary figures, which come from other published sources.
Citing journals

The journals whose papers most often cite retracted work as support.

Two ways to rank: the count favours large journals, the share is fairer to small ones. The census reads open-access papers, so journals that publish everything open access are counted in full and others in part: large open-access journals rank high on counts partly because more of their papers could be read. Compare journals by the share table. These are the journals that published the citing papers, not the retracted ones.

Why it matters: a journal's editors and peer reviewers are the last check before a paper is published. A reference to a retracted paper, used as support, can be caught at that stage by checking the reference list against a list of retractions.

Most citations of retracted work as support

Citing journals: most citations of retracted work as support
#Citing journalCited as supportSecond reading
1Int J Mol Sci609 papers cite retracted work as supportThey cite 561 different retracted papers as support. Most often: Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging (retracted 2016; 4 citations); 14 others have 3 citations each.653653 of 1,547 judged (42.2%)9 of 9
2Sci Rep568 papers cite retracted work as supportThey cite 521 different retracted papers as support. Most often: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin (retracted 2007; 4 citations) and Effect of zinc nanoparticles seed priming and foliar application on the growth and physio-biochemical indices of spinach (Spinacia oleracea L.) under salt stress (retracted 2022; 4 citations).580580 of 1,731 judged (33.5%)7 of 10
3PLoS One486 papers cite retracted work as supportThey cite 420 different retracted papers as support. Most often: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin (retracted 2007; 9 citations) and The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes (retracted 2011; 7 citations).496496 of 1,586 judged (31.3%)7 of 8
4Front Pharmacol320 papers cite retracted work as supportThey cite 324 different retracted papers as support. Most often: Anti-apoptosis mechanism of triptolide based on network pharmacology in focal segmental glomerulosclerosis rats (retracted 2020; 3 citations); 22 others have 2 citations each.348348 of 680 judged (51.2%)8 of 10
5Front Immunol299 papers cite retracted work as supportThey cite 277 different retracted papers as support. Most often: CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation (retracted 2011; 7 citations) and Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance (retracted 2013; 7 citations).326326 of 720 judged (45.3%)10 of 10
6Front Oncol269 papers cite retracted work as supportThey cite 290 different retracted papers as support. Most often: circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family (retracted 2019; 3 citations), Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/B-catenin signaling pathway (retracted 2019; 3 citations), KIF20A silence inhibits the migration, invasion and proliferation of non-small cell lung cancer and regulates the JNK pathway (retracted 2020; 3 citations) and m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis (retracted 2023; 3 citations).313313 of 629 judged (49.8%)8 of 91 of the papers read again has since been retracted (PMC10580988)
7Heliyon275 papers cite retracted work as supportThey cite 287 different retracted papers as support. Most often: Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma (retracted 2021; 3 citations); 8 others have 2 citations each.297297 of 648 judged (45.8%)7 of 91 of the papers read again has since been retracted (PMC11033103)
8Cancers (Basel)209 papers cite retracted work as supportThey cite 214 different retracted papers as support. Most often: IL-6 Secreted by Cancer-associated Fibroblasts Induces Tamoxifen Resistance in Luminal Breast Cancer (retracted 2014; 5 citations) and MicroRNA-221/222 Negatively Regulates Estrogen Receptor alpha and is Associated with Tamoxifen Resistance in Breast Cancer (retracted 2016; 4 citations).238238 of 544 judged (43.8%)6 of 9
9Molecules191 papers cite retracted work as supportThey cite 182 different retracted papers as support. Most often: Selective killing of cancer cells by a small molecule targeting the stress response to ROS (retracted 2018; 5 citations), Cyclodextrin-complexed Curcumin Exhibits Anti-inflammatory and Antiproliferative Activities Superior to Those of Curcumin Through Higher Cellular Uptake (retracted 2016; 3 citations), Updated knowledge about polyphenols: functions, bioavailability, metabolism, and health (retracted 2015; 3 citations) and Synthesis, characterization and catalytic activity of silver nanoparticles using Tribulus terrestris leaf extract (retracted 2016; 3 citations).203203 of 488 judged (41.6%)8 of 10
10Front Cell Dev Biol134 papers cite retracted work as supportThey cite 154 different retracted papers as support. Most often: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (retracted 2022; 3 citations); 7 others have 2 citations each.163163 of 295 judged (55.3%)8 of 8

Highest share as support, among journals with 100+ judged citations

Citing journals: highest share as support, among journals with 100+ judged citations
#Citing journalShare cited as supportSecond reading
1Front Mol Biosci57 papers cite retracted work as supportThey cite 69 different retracted papers as support. Most often: Oncolytic virotherapy with human telomerase reverse transcriptase promoter regulation enhances cytotoxic effects against gastric cancer (retracted 2021; 2 citations).60.3%70 of 116 judged (60.3%)9 of 9
2Cell Commun Signal54 papers cite retracted work as supportThey cite 63 different retracted papers as support. Most often: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA (retracted 2023; 2 citations).58.2%64 of 110 judged (58.2%)8 of 8
3Noncoding RNA Res42 papers cite retracted work as supportThey cite 65 different retracted papers as support.57.5%65 of 113 judged (57.5%)9 of 9
4Front Cell Dev Biol134 papers cite retracted work as supportThey cite 154 different retracted papers as support. Most often: Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells (retracted 2022; 3 citations); 7 others have 2 citations each.55.3%163 of 295 judged (55.3%)8 of 8
5Cancer Cell Int116 papers cite retracted work as supportThey cite 138 different retracted papers as support. Most often, 5 papers tie at 2 citations each, among them Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a (retracted 2023; 2 citations) and circRNA_100290 plays a role in oral cancer by functioning as a sponge of the miR-29 family (retracted 2019; 2 citations).55.2%143 of 259 judged (55.2%)7 of 9
6Onco Targets Ther62 papers cite retracted work as supportThey cite 61 different retracted papers as support. Most often: Baicalein inhibits proliferation and migration of bladder cancer cell line T24 by down-regulation of microRNA-106 (retracted 2020; 2 citations).53.9%62 of 115 judged (53.9%)6 of 71 of the papers read again has since been retracted (PMC6885654)
7Bioengineered76 papers cite retracted work as supportThey cite 79 different retracted papers as support. Most often: MicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway (retracted 2020; 2 citations), LncRNA MALAT1 regulates sepsis-induced cardiac inflammation and dysfunction via interaction with miR-125b and p38 MAPK/NFκB (retracted 2021; 2 citations) and Circ_0008035 contributes to cell proliferation and inhibits apoptosis and ferroptosis in gastric cancer via miR-599/EIF4A1 axis (retracted 2021; 2 citations).52.9%82 of 155 judged (52.9%)8 of 8
8Front Pharmacol320 papers cite retracted work as supportThey cite 324 different retracted papers as support. Most often: Anti-apoptosis mechanism of triptolide based on network pharmacology in focal segmental glomerulosclerosis rats (retracted 2020; 3 citations); 22 others have 2 citations each.51.2%348 of 680 judged (51.2%)8 of 10
9Discov Oncol92 papers cite retracted work as supportThey cite 105 different retracted papers as support. Most often: Exosomal long non-coding RNA UCA1 functions as growth inhibitor in esophageal cancer (retracted 2022; 2 citations).51.0%106 of 208 judged (51.0%)8 of 9
10Front Neurosci48 papers cite retracted work as supportThey cite 49 different retracted papers as support. Most often: Temporal activation of anti- and pro-apoptotic factors in human gingival fibroblasts infected with the periodontal pathogen, Porphyromonas gingivalis: potential role of bacterial proteases in host signalling (retracted 2019; 2 citations) and Transcutaneous vagus nerve stimulation (tVNS) enhances response selection during action cascading processes (retracted 2022; 2 citations).50.5%51 of 101 judged (50.5%)8 of 9

Second reading: 10 support citations per journal, drawn at random and read again. Later taken out of the samples: citations of work retracted for a reason that does not touch the results; citations that turned out to come before the retraction once the dates were checked; citations a full-text check found do not point to the retracted paper; and citations a later full-text check took out of scope. Across the lists' scope, 40.2% of citations are support (the census headline, which also counts papers PubMed does not yet link to a notice, is 40.7%). With 100 to 300 citations, a share can be off by several points either way, so close places in the second table are not real differences.

Citing authors

The authors whose papers most often cite retracted work as support.

This counts citations, not intent. It does not say anyone acted dishonestly, and it does not judge whether a review's conclusions still stand: most of these citations sit in review articles that sum up many earlier studies, often in a table, and a co-author may have written that part.

Why it matters: readers trust a review to sum up sound evidence. A retracted study counted as support can carry an unreliable result into the review, and from there into the work that cites the review.

The authors whose papers most often cite retracted work as support, ranked
#AuthorPapers citing retracted work as supportRateReviewsRetracted papers cited
1Mohammad TaheriORCID 0000-0001-8381-0591Co-wrote 22 of them with Bashdar Mahmud Hussen and 21 of them with Soudeh Ghafouri-Fard24of 26 found by the census10.5%of 228 tagged papers2334
The 24 papers and 34 citations
  1. MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets Front Oncol 2021 · review
    • Zhang D et al., Biomed Pharmacother 2016, retracted 2020. Notice reason: results See the passage · retraction noticeSubmitted 22 Sep 2020, before the retraction of 25 Nov 2020; accepted 30 Mar 2021 and published 22 Apr 2021, after it.
  2. X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis Front Cell Dev Biol 2021 · review
  3. The emerging role non-coding RNAs in B cell-related disorders Cancer Cell Int 2022 · review
    • Zeng H et al., Cancer Manag Res 2021, retracted 2021. Notice reason: results See the passage · retraction noticeSubmitted 9 Dec 2021, before the retraction of 23 Dec 2021; accepted and published (22 Feb 2022) after it.
  4. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features Front Cell Dev Biol 2022 · review
    • Zhao Z et al., Front Oncol 2020, retracted 2021. Notice reason: results See the passage · retraction noticeSubmitted 23 Jul 2021, before the retraction of 30 Dec 2021; accepted 4 Feb 2022 and published 25 Feb 2022, after it.
  5. The Role of Circular RNAs in the Carcinogenesis of Bladder Cancer Front Oncol 2022 · review
    • Feng F et al., Eur Rev Med Pharmacol Sci 2020, retracted 2021. Reason unclear ("serious inaccuracies and mistakes", not specified) See the passage · retraction notice
  6. Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins Front Oncol 2022 · review
  7. A review on the role of MCM3AP-AS1 in the carcinogenesis and tumor progression Cancer Cell Int 2022 · review
    • Wang H et al., Eur Rev Med Pharmacol Sci 2020, retracted 2021. Reason unclear (withdrawn "due to the discovery of new results") See the passage · retraction notice
  8. Aberrant expression of miRNAs in epilepsy Mol Biol Rep 2022 · review
  9. Assessment of Expression of Regulatory T Cell Differentiation Genes in Autism Spectrum Disorder Front Mol Neurosci 2022This paper has itself been retracted (Mar 2025). retraction notice
  10. Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers Cancer Cell Int 2022 · review
  11. Implication of non-coding RNA-mediated ROCK1 regulation in various diseases Front Mol Biosci 2022 · review
  12. Disease-associated regulation of gene expression by resveratrol: Special focus on the PI3K/AKT signaling pathway Cancer Cell Int 2022 · review
  13. Exosomal circular RNAs: New player in breast cancer progression and therapeutic targets Front Genet 2023 · review
  14. Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer Front Oncol 2023 · review
  15. Emerging functions and clinical applications of exosomal microRNAs in diseases Noncoding RNA Res 2023 · review
    • Mao R et al., Life Sci 2020, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 13 Feb 2023, before the retraction of 18 Feb 2023; accepted (7 May 2023) and published (9 May 2023) after it.
    • Tian J et al., Int Immunopharmacol 2021, retracted 2022. Notice reason: results See the passage · retraction notice
  16. Interaction between SIRT1 and non-coding RNAs in different disorders Front Genet 2023 · review
    • Li H et al., Life Sci 2021, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 12 Dec 2022, before the retraction of 18 Feb 2023; accepted (16 Jun 2023) and published (27 Jun 2023) after it.
    • Wang R et al., Front Physiol 2021, retracted 2022. Notice reason: results See the passage · retraction notice
  17. A review on the role of HAND2-AS1 in cancer Clin Exp Med 2023 · review
  18. Role of circular RNAs and gut microbiome in gastrointestinal cancers and therapeutic targets Noncoding RNA Res 2023 · review
  19. Antioxidant therapy against TGF-β/SMAD pathway involved in organ fibrosis J Cell Mol Med 2023 · review
    • Guo NF et al., Eur Rev Med Pharmacol Sci 2019, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 15 May 2023, before the retraction (July 2023); accepted 14 Nov 2023 and published 2 Dec 2023, after it.
  20. Advanced approaches of the use of circRNAs as a replacement for cancer therapy Noncoding RNA Res 2024 · review

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets Front Mol Biosci 2021 · review
  2. A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer Front Oncol 2021 · review
  3. Functional interplay between long non-coding RNAs and Breast CSCs Cancer Cell Int 2022 · review
  4. MiRNA-93: a novel signature in human disorders and drug resistance Cell Commun Signal 2023 · review
2Bashdar Mahmud HussenORCID 0000-0003-1060-6527Co-wrote 22 of them with Mohammad Taheri and 19 of them with Soudeh Ghafouri-Fard22of 24 found by the census17.7%of 124 tagged papers2132
The 22 papers and 32 citations
  1. The emerging role non-coding RNAs in B cell-related disorders Cancer Cell Int 2022 · review
    • Zeng H et al., Cancer Manag Res 2021, retracted 2021. Notice reason: results See the passage · retraction noticeSubmitted 9 Dec 2021, before the retraction of 23 Dec 2021; accepted and published (22 Feb 2022) after it.
  2. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features Front Cell Dev Biol 2022 · review
    • Zhao Z et al., Front Oncol 2020, retracted 2021. Notice reason: results See the passage · retraction noticeSubmitted 23 Jul 2021, before the retraction of 30 Dec 2021; accepted 4 Feb 2022 and published 25 Feb 2022, after it.
  3. The Role of Circular RNAs in the Carcinogenesis of Bladder Cancer Front Oncol 2022 · review
    • Feng F et al., Eur Rev Med Pharmacol Sci 2020, retracted 2021. Reason unclear ("serious inaccuracies and mistakes", not specified) See the passage · retraction notice
  4. Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins Front Oncol 2022 · review
  5. A review on the role of MCM3AP-AS1 in the carcinogenesis and tumor progression Cancer Cell Int 2022 · review
    • Wang H et al., Eur Rev Med Pharmacol Sci 2020, retracted 2021. Reason unclear (withdrawn "due to the discovery of new results") See the passage · retraction notice
  6. Aberrant expression of miRNAs in epilepsy Mol Biol Rep 2022 · review
  7. Assessment of Expression of Regulatory T Cell Differentiation Genes in Autism Spectrum Disorder Front Mol Neurosci 2022This paper has itself been retracted (Mar 2025). retraction notice
  8. Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers Cancer Cell Int 2022 · review
  9. Implication of non-coding RNA-mediated ROCK1 regulation in various diseases Front Mol Biosci 2022 · review
  10. Disease-associated regulation of gene expression by resveratrol: Special focus on the PI3K/AKT signaling pathway Cancer Cell Int 2022 · review
  11. Exosomal circular RNAs: New player in breast cancer progression and therapeutic targets Front Genet 2023 · review
  12. Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer Front Oncol 2023 · review
  13. Emerging functions and clinical applications of exosomal microRNAs in diseases Noncoding RNA Res 2023 · review
    • Mao R et al., Life Sci 2020, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 13 Feb 2023, before the retraction of 18 Feb 2023; accepted (7 May 2023) and published (9 May 2023) after it.
    • Tian J et al., Int Immunopharmacol 2021, retracted 2022. Notice reason: results See the passage · retraction notice
  14. Interaction between SIRT1 and non-coding RNAs in different disorders Front Genet 2023 · review
    • Li H et al., Life Sci 2021, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 12 Dec 2022, before the retraction of 18 Feb 2023; accepted (16 Jun 2023) and published (27 Jun 2023) after it.
    • Wang R et al., Front Physiol 2021, retracted 2022. Notice reason: results See the passage · retraction notice
  15. A review on the role of HAND2-AS1 in cancer Clin Exp Med 2023 · review
  16. Role of circular RNAs and gut microbiome in gastrointestinal cancers and therapeutic targets Noncoding RNA Res 2023 · review
  17. Antioxidant therapy against TGF-β/SMAD pathway involved in organ fibrosis J Cell Mol Med 2023 · review
    • Guo NF et al., Eur Rev Med Pharmacol Sci 2019, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 15 May 2023, before the retraction (July 2023); accepted 14 Nov 2023 and published 2 Dec 2023, after it.
  18. Advanced approaches of the use of circRNAs as a replacement for cancer therapy Noncoding RNA Res 2024 · review

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets Front Mol Biosci 2021 · review
  2. A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer Front Oncol 2021 · review
  3. Functional interplay between long non-coding RNAs and Breast CSCs Cancer Cell Int 2022 · review
  4. MiRNA-93: a novel signature in human disorders and drug resistance Cell Commun Signal 2023 · review
2Soudeh Ghafouri-FardORCID 0000-0002-0223-499XCo-wrote 21 of them with Mohammad Taheri and 19 of them with Bashdar Mahmud Hussen22of 24 found by the census8.2%of 268 tagged papers2128
The 22 papers and 28 citations
  1. MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets Front Oncol 2021 · review
    • Zhang D et al., Biomed Pharmacother 2016, retracted 2020. Notice reason: results See the passage · retraction noticeSubmitted 22 Sep 2020, before the retraction of 25 Nov 2020; accepted 30 Mar 2021 and published 22 Apr 2021, after it.
  2. X-Inactive-Specific Transcript: Review of Its Functions in the Carcinogenesis Front Cell Dev Biol 2021 · review
  3. The emerging role non-coding RNAs in B cell-related disorders Cancer Cell Int 2022 · review
    • Zeng H et al., Cancer Manag Res 2021, retracted 2021. Notice reason: results See the passage · retraction noticeSubmitted 9 Dec 2021, before the retraction of 23 Dec 2021; accepted and published (22 Feb 2022) after it.
  4. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features Front Cell Dev Biol 2022 · review
    • Zhao Z et al., Front Oncol 2020, retracted 2021. Notice reason: results See the passage · retraction noticeSubmitted 23 Jul 2021, before the retraction of 30 Dec 2021; accepted 4 Feb 2022 and published 25 Feb 2022, after it.
  5. The Role of Circular RNAs in the Carcinogenesis of Bladder Cancer Front Oncol 2022 · review
    • Feng F et al., Eur Rev Med Pharmacol Sci 2020, retracted 2021. Reason unclear ("serious inaccuracies and mistakes", not specified) See the passage · retraction notice
  6. Interplay Between Non-Coding RNAs and Programmed Cell Death Proteins Front Oncol 2022 · review
  7. A review on the role of MCM3AP-AS1 in the carcinogenesis and tumor progression Cancer Cell Int 2022 · review
    • Wang H et al., Eur Rev Med Pharmacol Sci 2020, retracted 2021. Reason unclear (withdrawn "due to the discovery of new results") See the passage · retraction notice
  8. Aberrant expression of miRNAs in epilepsy Mol Biol Rep 2022 · review
  9. Assessment of Expression of Regulatory T Cell Differentiation Genes in Autism Spectrum Disorder Front Mol Neurosci 2022This paper has itself been retracted (Mar 2025). retraction notice
  10. Role of PI3K/AKT pathway in squamous cell carcinoma with an especial focus on head and neck cancers Cancer Cell Int 2022 · review
  11. A review on the importance of miRNA-135 in human diseases Front Genet 2022 · review
  12. Implication of non-coding RNA-mediated ROCK1 regulation in various diseases Front Mol Biosci 2022 · review
  13. Disease-associated regulation of gene expression by resveratrol: Special focus on the PI3K/AKT signaling pathway Cancer Cell Int 2022 · review
  14. Exosomal circular RNAs: New player in breast cancer progression and therapeutic targets Front Genet 2023 · review
  15. Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer Front Oncol 2023 · review
  16. Emerging functions and clinical applications of exosomal microRNAs in diseases Noncoding RNA Res 2023 · review
    • Mao R et al., Life Sci 2020, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 13 Feb 2023, before the retraction of 18 Feb 2023; accepted (7 May 2023) and published (9 May 2023) after it.
    • Tian J et al., Int Immunopharmacol 2021, retracted 2022. Notice reason: results See the passage · retraction notice
  17. Interaction between SIRT1 and non-coding RNAs in different disorders Front Genet 2023 · review
    • Li H et al., Life Sci 2021, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 12 Dec 2022, before the retraction of 18 Feb 2023; accepted (16 Jun 2023) and published (27 Jun 2023) after it.
    • Wang R et al., Front Physiol 2021, retracted 2022. Notice reason: results See the passage · retraction notice
  18. A review on the role of HAND2-AS1 in cancer Clin Exp Med 2023 · review
  19. Antioxidant therapy against TGF-β/SMAD pathway involved in organ fibrosis J Cell Mol Med 2023 · review
    • Guo NF et al., Eur Rev Med Pharmacol Sci 2019, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 15 May 2023, before the retraction (July 2023); accepted 14 Nov 2023 and published 2 Dec 2023, after it.

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. MicroRNAs: Important Players in Breast Cancer Angiogenesis and Therapeutic Targets Front Mol Biosci 2021 · review
  2. A Review on the Role of AFAP1-AS1 in the Pathoetiology of Cancer Front Oncol 2021 · review
  3. Functional interplay between long non-coding RNAs and Breast CSCs Cancer Cell Int 2022 · review
4Michael R HamblinORCID 0000-0001-6431-46059of 9 found by the census4.9%of 184 tagged papers934
The 9 papers and 34 citations
  1. TGF-β and WNT signaling pathways in cardiac fibrosis: non-coding RNAs come into focus Cell Commun Signal 2020 · review
  2. Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis Cell Commun Signal 2020 · review
  3. Non-coding RNAs and glioblastoma: Insight into their roles in metastasis Mol Ther Oncolytics 2021 · reviewSubmission date not available. Published online 22 Dec 2021; the works it cites were retracted between July and November 2021.
  4. Lysophosphatidic Acid Signaling and microRNAs: New Roles in Various Cancers Front Oncol 2022 · review
  5. MicroRNA-383: A tumor suppressor miRNA in human cancer Front Cell Dev Biol 2022 · review
  6. Epigenetic regulation in myocardial infarction: Non-coding RNAs and exosomal non-coding RNAs Front Cardiovasc Med 2022 · review
  7. MiRNA-related metastasis in oral cancer: moving and shaking Cancer Cell Int 2023 · review
  8. MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis Front Oncol 2023 · reviewThis paper has itself been retracted (Sep 2026). An expression of concern came first, in Jan 2026. retraction notice
  9. Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy Cell Mol Life Sci 2024 · review
    • Smyth MJ et al., J Clin Oncol 2014, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 2 Jul 2023, before the retraction of 11 Aug 2023; revised 1 Oct 2023, accepted 29 Oct 2023 and published 29 Feb 2024, after it.

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. MiRNA-related metastasis in oral cancer: moving and shaking Cancer Cell Int 2023 · review
Reply from the author, received 22 Oct 2026Dr Hamblin says he has never knowingly cited a retracted paper and finds it hard to believe that anyone would. The papers in our letter all came from his collaborators in Iran, where internet access is sporadic, unreliable and slow, so researchers build a reference library when they have access and write from it later; a paper retracted after the library was built would not show as retracted, which he says explains our findings. He said none of these citations contains the word "retracted", though our letter said one reference list marked a work retracted.I have never knowingly cited a retracted paper and frankly I find it difficult to believe that anybody would knowingly do thisOur response: He was right about the one item our letter marked: its reference carries a link to the retraction notice, most likely added during publication. For every author, such items now sit apart under their own heading, with a note that publishers often add these links and labels, so they do not show that the authors knew. The other citations stay counted, because the reviews were published after the retractions.Changes since our letter:
  • Every author: an item whose published reference list links the retraction notice or labels the work retracted now sits apart under the heading "The published reference list links the retraction notice or labels the work retracted", with a note that publishers often add such links and labels during publication, so they do not show that the authors knew.
  • Wu L et al. (Cell Biol Int) left out under the rule for retractions that do not touch the results (a missing copyright form), so his 2022 review on retinoblastoma is no longer counted.
  • Timelines printed beside two reviews: his 2021 Mol Ther Oncolytics review (no submission date available; online 22 Dec 2021, after the cited works were retracted between July and November 2021) and his 2024 Cell Mol Life Sci review (submitted 2 Jul 2023, before the retraction of 11 Aug 2023).
  • Xie P et al. (Cancer Biomark 2017): our letter gave the retraction year as 2022; the page gives the notice's year, 2023, with its online date (2 Dec 2022).
  • The page now notes that his 2023 Front Oncol review was itself retracted (Sep 2026), after an expression of concern in Jan 2026.
  • His entry: from 10 papers and 35 citations in our letter to 9 papers and 34 citations, all in reviews.
5Javad Sharifi-RadORCID 0000-0002-7301-81518of 8 found by the census3.1%of 262 tagged papers88
The 8 papers and 8 citations
  1. Pharmacological Activities of Psoralidin: A Comprehensive Review of the Molecular Mechanisms of Action Front Pharmacol 2020 · review
  2. Therapeutic Applications of Curcumin in Diabetes: A Review and Perspective Biomed Res Int 2022 · review
  3. The Pharmacological Activities of Crocus sativus L.: A Review Based on the Mechanisms and Therapeutic Opportunities of its Phytoconstituents Oxid Med Cell Longev 2022 · review
  4. Apoptosis evasion via long non-coding RNAs in colorectal cancer Cancer Cell Int 2022 · review
  5. Ursolic acid: a natural modulator of signaling networks in different cancers Cancer Cell Int 2022 · review
  6. LncRNA SNHG6 role in clinicopathological parameters in cancers Eur J Med Res 2023 · review
  7. Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties Eur J Med Res 2024 · review

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. Artemisia spp.: An Update on Its Chemical Composition, Pharmacological and Toxicological Profiles Oxid Med Cell Longev 2022 · review
6Abdelhakim BouyahyaORCID 0000-0001-9317-16317of 8 found by the census4.9%of 142 tagged papers79
The 7 papers and 10 citations
  1. Natural Bioactive Compounds Targeting Epigenetic Pathways in Cancer: A Review on Alkaloids, Terpenoids, Quinones, and Isothiocyanates Nutrients 2021 · review
  2. The Pharmacological Activities of Crocus sativus L.: A Review Based on the Mechanisms and Therapeutic Opportunities of its Phytoconstituents Oxid Med Cell Longev 2022 · review
  3. The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions Biomolecules 2022 · review
  4. Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates Molecules 2022 · review
  5. Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy Cancers (Basel) 2022 · review
  6. Clinical applications and mechanism insights of natural flavonoids against type 2 diabetes mellitus Heliyon 2024 · review

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. Natural Bioactive Compounds Targeting Epigenetic Pathways in Cancer: A Review on Alkaloids, Terpenoids, Quinones, and Isothiocyanates Nutrients 2021 · review
  2. Targeting inflammation in cancer therapy: from mechanistic insights to emerging therapeutic approaches J Transl Med 2025 · review
7Anupam BishayeeORCID 0000-0001-9159-960X6of 8 found by the census6.9%of 87 tagged papers46
The 6 papers and 6 citations
  1. Autophagy: A Potential Therapeutic Target of Polyphenols in Hepatocellular Carcinoma Cancers (Basel) 2020 · review
  2. Sulforaphane: A Broccoli Bioactive Phytocompound with Cancer Preventive Potential Cancers (Basel) 2021 · review
  3. Anticancer Potential of Apigenin and Isovitexin with Focus on Oncogenic Metabolism in Cancer Stem Cells Metabolites 2023 · review
  4. Naringin-Dextrin Nanocomposite Abates Diethylnitrosamine/Acetylaminofluorene-Induced Lung Carcinogenesis by Modulating Oxidative Stress, Inflammation, Apoptosis, and Cell Proliferation Cancers (Basel) 2023
  5. Bioactive black tea phytochemicals partially influenced doxorubicin sensitivity by modulation of NRF2-regulatory pathways in lung cancer J Ayurveda Integr Med 2026

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. Phytochemicals for the Prevention and Treatment of Renal Cell Carcinoma: Preclinical and Clinical Evidence and Molecular Mechanisms Cancers (Basel) 2022 · review
7Meysam MoghbeliORCID 0000-0001-9680-03096of 7 found by the census18.2%of 33 tagged papers610
The 6 papers and 10 citations
  1. MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells Genes Environ 2021 · review
    • Cao HY et al., Eur Rev Med Pharmacol Sci 2019, retracted 2020. Notice reason: results See the passage · retraction noticeFirst submitted in Mar 2019, the author says, before the retraction (November 2020); received by this journal 20 Feb 2021, accepted (24 May 2021) and published (7 Jun 2021) after it.
  2. Long non-coding RNAs as the critical regulators of epithelial mesenchymal transition in colorectal tumor cells: an overview Cancer Cell Int 2022 · review
    • Wang Z et al., Cancer Res 2006, retracted 2018. Notice reason: results See the passage · retraction noticeFirst submitted in Jul 2018, the author says, before the retraction (September 2018); received by this journal 13 Nov 2021, accepted (30 Jan 2022) and published (10 Feb 2022) after it.
  3. Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population Hum Genomics 2022 · review
    • Golsheh S et al., Diabetes Metab Syndr Obes 2019, retracted 2019. Notice reason: results See the passage · retraction noticeFirst submitted in May 2019, the author says, before the retraction (July 2019); received by this journal 22 Dec 2021, accepted (23 Mar 2022) and published (2 Apr 2022) after it.
  4. MicroRNAs as the critical regulators of cell migration and invasion in thyroid cancer Biomark Res 2022 · reviewFirst submitted in Mar 2021, the author says, before the five retractions (June to October 2021); received by this journal 4 Jan 2022, accepted (7 May 2022) and published (4 Jun 2022) after them.
  5. Cell cycle related long non-coding RNAs as the critical regulators of breast cancer progression and metastasis Biol Res 2023 · review
    • Hu CC et al., Eur Rev Med Pharmacol Sci 2019, retracted 2022. Notice reason: results See the passage · retraction noticeSubmitted 17 Nov 2021, before the retraction (September 2022); accepted (29 Dec 2022) and published (3 Jan 2023) after it.
  6. MicroRNAs as the critical regulators of epithelial mesenchymal transition in pancreatic tumor cells Heliyon 2024 · review
    • Peng L et al., Oncol Rep 2017, retracted 2023. Notice reason: results See the passage · retraction noticeFirst submitted in Jan 2023, the author says, before the retraction (February 2023); received by this journal 26 Feb 2024, accepted (30 Apr 2024) and published (1 May 2024) after it.
Reply from the author, received 22 Oct 2026In two replies, Dr Moghbeli confirms that the citations are correct. He says each review was finished and first submitted before the cited papers were retracted. In his second reply he adds that the six reviews were submitted, rejected and passed from journal to journal over long periods, often through Springer's transfer to the next journal it suggested, and that the retractions came during those transfers. Once a manuscript is under review, authors cannot change it unless the journal sends it back, and journals did not then check references for retractions as they do now; so he says authors cannot find such references unless the journal checks them and asks for a correction, and that such citations are inevitable in reviews with hundreds of references that pass through several journals. He says the retracted references, 11 of the 1,546 in the seven reviews, have no significant negative effect on the reviews' topics or conclusions. He also said the first item, Roberts JT et al. (Ann Oncol 2006), is not retracted and has no retraction notice.When we wrote, prepared, and submitted these review manuscripts, the cited papers were not yet retracted.Our response: The record he checked is the original 2005 trial in J Clin Oncol, which is not retracted; the Ann Oncol 2006 paper was retracted in 2011 as a redundant publication of it, and had already been left out under the rule for duplicates. His timelines match the journal records and the notices and are printed beside each review; those citations stay counted, because the reviews were published after the retractions. His second reply explains how the manuscripts moved between journals; it changes no entry.Changes since our letter:
  • Roberts JT et al. (Ann Oncol 2006) is left out (retracted in 2011 as a redundant publication of results that stay published in J Clin Oncol), so his 2020 Cell Commun Signal review is not counted.
  • Timelines printed beside the six remaining reviews: first-submission dates from his account, the rest from the journal records and the retraction notices.
  • His entry: from 7 papers and 11 citations in our letter to 6 papers and 10 citations, all in reviews.
7Amirhossein SahebkarORCID 0000-0002-8656-14446of 6 found by the census4.2%of 144 tagged papers69
The 6 papers and 9 citations
  1. Effect of COVID-19 on Mortality of Pregnant and Postpartum Women: A Systematic Review and Meta-Analysis J Pregnancy 2021 · review
    • Karami P et al., Travel Med Infect Dis 2020, retracted 2020. Reason unclear (withdrawn at the authors' request, no reason given) See the passage · retraction notice
  2. Harnessing the Therapeutic Potential of Decoys in Non-Atherosclerotic Cardiovascular Diseases: State of the Art J Cardiovasc Dev Dis 2021 · review
  3. The Multifaceted Therapeutic Mechanisms of Curcumin in Osteosarcoma: State-of-the-Art J Oncol 2021 · review
  4. MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer J Oncol 2021 · review
  5. Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer J Oncol 2022 · review
  6. Impact of Phytochemicals on PPAR Receptors: Implications for Disease Treatments PPAR Res 2022 · review

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer J Oncol 2022 · review
Reply from the author, received 21 Oct 2026Dr Sahebkar says a retraction is not a single verdict on a paper: notices range from fabricated data to duplicate publication, authorship disputes or a problem in one figure unrelated to the result being cited, and COPE guidance recommends citing retracted work with its status clearly marked. Whether a citation is a problem depends on whether the reason for retraction touches the statement it supports and whether the citing paper's conclusion rests on it, which a count of citations cannot answer. All seven papers in our letter are reviews of hundreds of sources, and he says none of their conclusions depends on the retracted papers. He asks that authors be compared by rates normalised by their total publications and cited references, not ranked by absolute counts, since a ranking by count is led by the authors who publish most. He was given the opportunity to send a direct response for publication instead of this summary.Our response: Two of his points changed the lists for every author: the author list now shows a rate beside each count (for him, 6 of 144 papers, 4.2%), and citations of work retracted for reasons that do not touch its results are left out. The ranking stays by count, as set out in advance, and the rate counts papers, not references.Changes since our letter:
  • Every author: a rate is shown beside the count (papers citing retracted work as support, out of the author's open-access papers in PMC tagged with their ORCID iD, 2010 to 2026).
  • Every list: citations of work retracted only for reasons that do not touch the results are left out. Two of his items came off: Zhang P et al. (J Exp Clin Cancer Res 2017; the notice concerns the welfare of the mice and ethics approval) and Wu L et al. (Cell Biol Int; a signed copyright transfer agreement was not provided).
  • His entry: from 7 papers and 11 citations in our letter to 6 papers and 9 citations, all in reviews.
7Noushin NabaviORCID 0000-0002-5471-62296of 7 found by the census16.7%of 36 tagged papers610
The 6 papers and 10 citations
  1. The long and short non-coding RNAs modulating EZH2 signaling in cancer J Hematol Oncol 2022 · review
  2. Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance Cell Mol Biol Lett 2023 · review
  3. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer Transl Oncol 2023 · review
    • Jiang Z et al., Bioengineered 2022, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 21 Sep 2023, before the retraction of 18 Oct 2023; revised 9 Nov 2023, accepted 20 Nov 2023 and published 1 Dec 2023, after it.
  4. NF-ĸB axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies Heliyon 2024 · reviewThis paper has itself been retracted (Dec 2025). Its authors dispute the retraction. retraction notice
  5. Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer Noncoding RNA Res 2024 · review
  6. Highlighting function of Wnt signalling in urological cancers: Molecular interactions, therapeutic strategies, and (nano)strategies Transl Oncol 2024 · review
Reply from the author, received 21 Oct 2026Dr Nabavi checked the references and passages and accepts that the cited studies have retraction notices and are cited in support of statements in her reviews, but says this does not by itself show prior awareness, misconduct, or that the reviews' overall conclusions are invalid. She notes that her oxaliplatin review was submitted on 21 September 2023, before the cited circPTK2 study was retracted on 18 October 2023, though it was revised and published afterwards. She would need to review the manuscript history before giving an account of awareness, and is willing to work with her co-authors and the journals to assess the affected statements and pursue appropriate corrections. She asked that her entry be deferred until she has seen and answered the human check's findings, and that her response be published alongside her entry; it is printed below as she wrote it.Citation counts alone cannot establish that an entire review is unreliable.Statement from the author, printed as written:

Thank you for contacting me before publication and providing an opportunity to respond. I take the accuracy of the scientific record seriously.

I have checked the identified references and their surrounding passages. I acknowledge that the listed studies have retraction notices and are cited in support of scientific statements in the reviews. However, this does not, by itself, establish prior awareness of the retractions, individual misconduct, or that the reviews’ overall conclusions are invalid.

The publication timeline requires context. The oxaliplatin review was submitted on 21 September 2023, before the cited circPTK2 study was retracted on 18 October 2023, although the review was revised and published afterward. Please reflect this distinction in your account.

It is also important to distinguish the status of a review from that of a study it cites. For example, the May 2022 correction to “The long and short non-coding RNAs modulating EZH2 signaling in cancer” concerned a co-author’s name; it was not a retraction of that review. I recognise that this correction does not resolve the separate issue of its cited sources.

Regarding prior awareness, I would need to review the manuscript history and relevant correspondence before providing an accurate account for each citation. Assessing the effect on the reviews’ conclusions likewise requires examining the particular claims and the remaining evidence. Citation counts alone cannot establish that an entire review is unreliable. I remain willing to work with the co-authors and journals to assess the affected statements and pursue appropriate corrections.

I also have concerns about the opportunity afforded to authors to respond to editorial decisions. In some instances involving our own papers, my understanding is that we were notified only after retraction and were not given a meaningful opportunity to respond beforehand. This is a separate concern from the status of the studies cited in those papers.

Regarding the separate Elsevier retraction matter, I continue to disagree strongly with the decision and dispute the grounds provided. In our correspondence with Elsevier, we explained our position that the identified reference mismatches and Table 3 error could be addressed through a formal correction without invalidating the review’s overall conclusions. We supplied proposed corrections and requested a specific explanation of why a correction was considered insufficient. In our view, those concerns were not adequately addressed.

Please distinguish this disputed editorial matter from your citation analysis. If you discuss it, please accurately record that the authors disagree with the retraction and dispute its grounds.

I appreciate your clarification that your analysis concerns citation use rather than intent. Please preserve that distinction in the published presentation. As your figures remain provisional and human verification is pending, please provide the completed human-review findings when available. I request that publication of my individual entry be deferred until I have had a reasonable opportunity to review and respond to those findings.

I would welcome publication of this response alongside any summary concerning me, so that readers can consider my position in context.

Our response: Her dates are exact, and the timeline is printed beside that citation; it stays counted, because every entry is measured by the paper as published. We did not defer her entry, since the list is published whole. If she shows that a reading is wrong, we correct the entry and say so here.Changes since our letter:
  • Timeline printed beside her Translational Oncology review's citation of Jiang Z et al. (Bioengineered 2022): submitted 21 Sep 2023, before the retraction of 18 Oct 2023; revised, accepted and published (1 Dec 2023) after it.
  • Xie P et al. (Cancer Biomark 2017): our letter gave the retraction year as 2022; the page gives the notice's year, 2023, with its online date (2 Dec 2022).
  • The page now notes that her 2024 Heliyon review was itself retracted (Dec 2025) and that its authors dispute the retraction.
7Gautam SethiORCID 0000-0002-8677-84756of 7 found by the census3.1%of 195 tagged papers57
The 6 papers and 7 citations
  1. Artesunate suppresses tumor growth and induces apoptosis through the modulation of multiple oncogenic cascades in a chronic myeloid leukemia xenograft mouse model Oncotarget 2015
  2. Potential of Zerumbone as an Anti-Cancer Agent Molecules 2019 · review
  3. Cytoskeletal Proteins in Cancer and Intracellular Stress: A Therapeutic Perspective Cancers (Basel) 2020 · review
  4. Circular RNAs in cell cycle regulation: Mechanisms to clinical significance Cell Prolif 2021 · review
  5. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling J Hematol Oncol 2022 · review
  6. The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer Front Endocrinol (Lausanne) 2023 · review
7Chih-Yang HuangORCID 0000-0003-2347-04116of 6 found by the census2.9%of 204 tagged papers16
The 6 papers and 6 citations
  1. Heat-killed Lactobacillus Reuteri GMNL-263 Prevents Epididymal Fat Accumulation and Cardiac Injury in High-Calorie Diet-Fed Rats Int J Med Sci 2016
  2. FOXC1 Regulation of miR-31-5p Confers Oxaliplatin Resistance by Targeting LATS2 in Colorectal Cancer Cancers (Basel) 2019
  3. Swimming exercise stimulates IGF1/ PI3K/Akt and AMPK/SIRT1/PGC1α survival signaling to suppress apoptosis and inflammation in aging hippocampus Aging (Albany NY) 2020
  4. E3 ligase activity of Carboxyl terminus of Hsc70 interacting protein (CHIP) in Wharton's jelly derived mesenchymal stem cells improves their persistence under hyperglycemic stress and promotes the prophylactic effects against diabetic cardiac damages Bioeng Transl Med 2021
  5. A prospective review of the health-promoting potential of Jing Si Herbal Tea Tzu Chi Med J 2024 · review
    • Zhu Z et al., J Healthc Eng 2021, retracted 2023. Notice reason: results See the passage · retraction noticeSubmitted 9 Aug 2023 and accepted 2 Oct 2023, both before the retraction of 6 Dec 2023; published (12 Jan 2024) after it.
  6. miR-6126 modulates GRP78 to suppress the Warburg effect and mitochondrial dynamics in triple-negative breast cancer Int J Med Sci 2025
7Peng LuoORCID 0000-0002-8215-20456of 6 found by the census2.3%of 259 tagged papers36
The 6 papers and 6 citations
  1. Comparison of the benefits of celecoxib combined with anticancer therapy in advanced non-small cell lung cancer: A meta-analysis J Cancer 2020
  2. Machine learning and experimental validation of novel biomarkers for hypertrophic cardiomyopathy and cancers J Cell Mol Med 2024
  3. Multi-stage mechanisms of tumor metastasis and therapeutic strategies Signal Transduct Target Ther 2024 · review
  4. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition J Hematol Oncol 2025 · review
  5. Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches Biomark Res 2025 · review

The published reference list links the retraction notice or labels the work retracted

Publishers often add these links and labels during publication, so they do not show that the authors knew.

  1. A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning Elife 2025
    • Liu J et al., Tumour Biol 2014, retracted 2015. Reason unclear (the notice says only that "the peer review process was compromised") See the passage · retraction notice

Papers: citing papers with at least one citation the second reading confirmed as support. Rate: those papers as a share of the author's open-access papers in PMC that carry their ORCID iD in Europe PMC, 2010 to 2026 (counted 2026-10-21). The ranking stays by count. The order does not hold under rates, even among the top three: authors with few tagged papers can have high rates on small numbers. Reviews: how many of those papers Europe PMC lists as review articles. Every support citation in every listed author's papers was read again (153 different citations; 217 author items, because the 3 authors who share papers wrote most of them together, so their counts overlap). Ties share a place.

Each listed item names the notice's reason. Results: the notice names a problem with the data, images or results, or says they cannot be relied on. Unclear: it gives no reason or a vague one, or we have not read it yet; these still count. Citations of work retracted only for reasons that do not touch the results are left out, as the census leaves out paperwork retractions. Where a citing paper was submitted or accepted before the retraction, its timeline is printed beside the item; papers that went online before the retraction are left out. 22 of the 200 items sit apart: the citing paper's published reference list links the retraction notice or labels the work retracted, in the reference as the publisher printed it (a retraction link PMC or Europe PMC shows beside a reference is not counted). Such labels and links are often added automatically during publication, so they do not show that the authors knew.

The full ranked tables

Every retracted paper (11,649) and every citing journal (3,807) in the lists' scope, ranked by the citations the census AI models labelled as support, with this page's corrections applied. Only the listed entries and the papers near the last place were read again.

All 11,649 papers (CSV) · All 3,807 journals (CSV) · What the tables hold

Also written to

Journals and authors below the cut.

These are not ranked. Each was sent its findings on 30 October or 1 November 2026, with until 8 Nov 2026 to reply. They are the entries just below the lists whose citations we read again. Each item is a paper that cites retracted work; under it are the retracted paper it cites and a link to the retraction notice.

Cell Death Discovery Journal · 59 of 117 citations cited as support (50.4%); we read 9 again and 6 held up. Written to 1 Nov 2026.

Reply: none received by 8 Nov 2026.

  1. Nuclear SPHK2/S1P induces oxidative stress and NLRP3 inflammasome activation via promoting p53 acetylation in lipopolysaccharide-induced acute lung injury. Cell Death Discovery 2023.
    • cites Puneet P et al., Science 2010, retracted 26 Jul 2013: SphK1 regulates proinflammatory responses associated with endotoxin and polymicrobial sepsis (notice)
  2. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Cell Death Discovery 2017.
    • cites Kumar MS et al., Nature 2014, retracted 10 Jun 2015: HMGA2 functions as a competing endogenous RNA to promote lung cancer progression (notice)
  3. Non-coding RNAs in necroptosis, pyroptosis and ferroptosis in cancer metastasis. Cell Death Discovery 2021.
    • cites Qu A et al., PLoS One 2014, retracted 17 Dec 2020: Hypoxia-inducible MiR-210 is an independent prognostic factor and contributes to metastasis in colorectal cancer (notice)
  4. Long non-coding RNAs and autophagy: dual drivers of Hepatocellular carcinoma progression. Cell Death Discovery 2025.
    • cites Chen Y et al., Mol Ther Nucleic Acids 2020, retracted 11 Dec 2022: LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells (notice)
  5. Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer. Cell Death Discovery 2022.
    • cites Zhang B et al., Anat Rec (Hoboken) 2021, retracted 28 Oct 2021: Alpinumisoflavone triggers GSDME-dependent pyroptosis in esophageal squamous cell carcinomas (notice)
    • cites Yin H et al., Anat Rec (Hoboken) 2021, retracted 28 Oct 2021: Resibufogenin suppresses growth and metastasis through inducing caspase-1-dependent pyroptosis via ROS-mediated NF-κB suppression in non-small cell lung cancer (notice)
Cells Journal · 152 of 376 citations cited as support (40.4%); we read 10 again and 3 held up. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders. Cells 2020.
    • cites Briones TL et al., J Neuroinflammation 2014, retracted 26 Nov 2015: Chronic neuroinflammation and cognitive impairment following transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling (notice)
  2. BDNF Modulation by microRNAs: An Update on the Experimental Evidence. Cells 2024.
    • cites Zhang J et al., Neurochem Res 2018, retracted 25 Jun 2020: MicroRNA-322 Cluster Promotes Tau Phosphorylation via Targeting Brain-Derived Neurotrophic Factor (notice)
  3. Circular RNA hsa_circ_0008726 Targets the hsa-miR-206-3p/KLF4 Axis to Modulate 4,4'-Methylene Diphenyl Diisocyanate-Glutathione Conjugate-Induced Chemokine Transcription in Macrophages. Cells 2024.
    • cites Wang M et al., Onco Targets Ther 2019, retracted 18 May 2022: Silencing circZFR inhibits the proliferation, migration and invasion of human renal carcinoma cells by regulating miR-206 (notice)
Cureus Journal · 136 of 330 citations cited as support (41.2%); we read 8 again and 4 held up. Written to 1 Nov 2026.

Reply (1 Nov 2026): The journal’s support desk answered our letter (1 November) and our reminder (4 November) with automatic notes saying each had been passed to a member of its team. No other reply came by 8 November. In their words: Your request has been reviewed and is being escalated to a member of our team for further assistance.

  1. Association Between Depression and Medication Adherence Among Post-myocardial Infarction Patients in a South Asian Clinical Setting. Cureus 2025.
    • cites Morisky DE et al., J Clin Hypertens 2008, retracted 18 Aug 2023: Predictive validity of a medication adherence measure in an outpatient setting (notice)
  2. Molecular Mechanisms and Treatment Strategies for Helicobacter pylori-Induced Gastric Carcinogenesis and Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Cureus 2024.
    • cites Zhou X et al., PLoS One 2014, retracted 22 Oct 2020: Decreased miR-204 in H. pylori-associated gastric cancer promotes cancer cell proliferation and invasion by targeting SOX4 (notice)
  3. Revisional Single-Anastomosis Gastric Bypass for a Patient With Severe Protein-Calorie Malnutrition: A Case Report. Cureus 2023.
    • cites Ruiz-Tovar J et al., Surg Endosc 2019, retracted 16 Jan 2021: Long-term follow-up after sleeve gastrectomy versus Roux-en-Y gastric bypass versus one-anastomosis gastric bypass: a prospective randomized comparative study of weight loss and remission of comorbidities (notice)
  4. Postoperative Pain Following Transoral Thyroidectomy via Vestibular Approach and Cervical Thyroidectomy: A Systematic Review and Meta-Analysis. Cureus 2024.
    • cites Yang C et al., J Healthc Eng 2022, retracted 4 Oct 2023: Discussion on the Transoral Vestibular Approach Endoscopy for TC Patients and the Significance of Serum 25-Hydroxyvitamin D Classification (notice)
Frontiers in Cardiovascular Medicine Journal · 74 of 152 citations cited as support (48.7%); we read 10 again and 6 held up. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. Piperlongumine Attenuates High Calcium/Phosphate-Induced Arterial Calcification by Preserving P53/PTEN Signaling. Frontiers in Cardiovascular Medicine 2020.
    • cites Raj L et al., Nature 2011, retracted 25 Jul 2018: Selective killing of cancer cells by a small molecule targeting the stress response to ROS (notice)
  2. Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications. Frontiers in Cardiovascular Medicine 2023.
    • cites Kohrt HE et al., J Clin Invest 2012, retracted 3 Jun 2019: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (notice)
  3. Roles of MicroRNAs in Glucose and Lipid Metabolism in the Heart. Frontiers in Cardiovascular Medicine 2021.
    • cites Nagalingam RS et al., J Biol Chem 2013, retracted 24 Mar 2017: A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling (notice)
  4. Epigenetic regulation in myocardial infarction: Non-coding RNAs and exosomal non-coding RNAs. Frontiers in Cardiovascular Medicine 2022.
    • cites Kong F et al., Biomed Pharmacother 2019, retracted 9 Dec 2021: Long noncoding RNA RMRP upregulation aggravates myocardial ischemia-reperfusion injury by sponging miR-206 to target ATG3 expression (notice)
  5. MicroRNAs as regulators of cardiac dysfunction in sepsis: pathogenesis and diagnostic potential. Frontiers in Cardiovascular Medicine 2025.
    • cites Ouyang H et al., Int Immunopharmacol 2020, retracted 21 Feb 2023: MicroRNA-208-5p regulates myocardial injury of sepsis mice via targeting SOCS2-mediated NF-κB/HIF-1α pathway (notice)
  6. Association of serum coiled-coil domain containing protein 11 levels with coronary artery disease. Frontiers in Cardiovascular Medicine 2026.
    • cites Zhou C et al., Onco Targets Ther 2020, retracted 9 Jun 2023: CCDC7 Activates Interleukin-6 and Vascular Endothelial Growth Factor to Promote Proliferation via the JAK-STAT3 Pathway in Cervical Cancer Cells (notice)
Journal of Cancer Journal · 94 of 187 citations cited as support (50.3%); we read 9 again and 8 held up. Written to 1 Nov 2026.

Reply: none received by 8 Nov 2026.

  1. Critical role and its underlying molecular events of the plasminogen receptor, S100A10 in malignant tumor and non-tumor diseases. Journal of Cancer 2020.
    • cites Li Q et al., Mol Immunol 2010, retracted 23 Nov 2011: A role for the annexin A2 amino-terminal peptide in the plasmin-induced activation of human peripheral monocytes (notice)
  2. FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/β-catenin Signaling Pathway. Journal of Cancer 2017.
    • cites Xing XJ et al., Tumour Biol 2014, retracted 17 Aug 2015: Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis (notice)
  3. FSCN1 acts as a promising therapeutic target in the blockade of tumor cell motility: a review of its function, mechanism, and clinical significance. Journal of Cancer 2022.
    • cites Zheng K et al., Oncol Lett 2015, retracted 8 Jul 2021: MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1 (notice)
  4. Potential impact and mechanism of Long Non-coding RNAs on cancer and associated T cells. Journal of Cancer 2021.
    • cites Fan FY et al., Int J Oncol 2017, retracted 22 Dec 2020: The inhibitory effect of MEG3/miR-214/AIFM2 axis on the growth of T-cell lymphoblastic lymphoma (notice)
  5. Prognostic Value and Immune Landscapes of Four Types of RNA Modification Writer-Related LncRNAs Signature in Lung Adenocarcinoma. Journal of Cancer 2024.
    • cites Xiu DH et al., J Exp Clin Cancer Res 2019, retracted 27 Oct 2021: Long non-coding RNA LINC00968 attenuates drug resistance of breast cancer cells through inhibiting the Wnt2/β-catenin signaling pathway by regulating WNT2 (notice)
  6. Circular RNA circASPM promotes the progression of glioblastoma by acting as a competing endogenous RNA to regulate miR-130b-3p/E2F1 axis. Journal of Cancer 2022.
    • cites Xie Y et al., Eur Rev Med Pharmacol Sci 2019, retracted Jul 2020: Long noncoding RNA CASC15 is upregulated in glioma and facilitates cell proliferation and metastasis via targeting miR-130b-3p (notice)
  7. MiR-675 Inhibits Primary Ovarian Tumor Growth and Metastasis by Suppressing EMT and TGFβ Signaling. Journal of Cancer 2025.
    • cites Wang J et al., Onco Targets Ther 2019, retracted 4 Oct 2021: MicroRNA-675 directly targets MAPK1 to suppress the oncogenicity of papillary thyroid cancer and is sponged by long non-coding RNA RMRP (notice)
  8. FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma. Journal of Cancer 2024.
    • cites Le Y et al., Comput Math Methods Med 2022, retracted 29 Nov 2023: Prognostic and Immunological Significance of FUNDC1 in Hepatocellular Carcinoma: A Study on TCGA Mining (notice)
Medicine Journal · 160 of 380 citations cited as support (42.1%); we read 9 again and 7 held up. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. Association between PTGER4 polymorphisms and inflammatory bowel disease risk in Caucasian: A meta-analysis. Medicine 2020.
    • cites Subbaramaiah K et al., J Biol Chem 2004, retracted 3 Jan 2020: Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1 (notice)
  2. Mining and validating the expression pattern and prognostic value of acetylcholine receptors in non-small cell lung cancer. Medicine 2019.
    • cites Paleari L et al., Cell Prolif 2008, retracted 29 Aug 2017: Role of alpha7-nicotinic acetylcholine receptor in human non-small cell lung cancer proliferation (notice)
  3. Genetically confirmed limb-girdle muscular dystrophy type 2B with DYSF mutation using gene panel sequencing: A case report. Medicine 2020.
    • cites Azakir BA et al., J Biol Chem 2012, retracted 28 Jul 2017: Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells (notice)
  4. Central metabolites and peripheral parameters associated neuroinflammation in fibromyalgia patients: A preliminary study. Medicine 2023.
    • cites Briones TL et al., Acta Neuropathol Commun 2013, retracted 17 May 2022: Decreased neuroinflammation and increased brain energy homeostasis following environmental enrichment after mild traumatic brain injury is associated with improvement in cognitive function (notice)
  5. Effect of miR-145 on intracardiac thrombosis in patients with rheumatic heart disease complicated with atrial fibrillation: A retrospective analysis. Medicine 2023.
    • cites Li L et al., Phytother Res 2020, retracted 7 Aug 2020: Baicalin relieves TNF-α-evoked injury in human aortic endothelial cells by up-regulation of miR-145 (notice)
  6. A bibliometric analysis of the published studies in ciprofol research. Medicine 2025.
    • cites Ludbrook G et al., Anesth Analg 2021, retracted 15 Jun 2021: Assessments of Onset and Duration of Drug Effects and Pharmacokinetics by Dose Level of HSK3486, a New Sedative-Hypnotic Agent, in Healthy Female/Male Subjects: A Phase I Multiarm Randomized Controlled Clinical Trial (notice) The reference list marks it retracted.
  7. Effect of ultrasound-guided nerve blocks on anesthesia and pulmonary function in patients undergoing distal radius fracture surgery. Medicine 2024.
    • cites Cai Q et al., J Healthc Eng 2022, retracted 4 Oct 2023: Analysis of the Effect of Applying Ultrasound-Guided Nerve Block Anesthesia to Fracture Patients in the Context of Internet-Based Blockchain (notice)
Oncology Reports Journal · 51 of 109 citations cited as support (46.8%); we read 7 again and 6 held up. Written to 1 Nov 2026.

Reply: none received by 8 Nov 2026.

  1. Silymarin induces inhibition of growth and apoptosis through modulation of the MAPK signaling pathway in AGS human gastric cancer cells. Oncology Reports 2019.
    • cites Vaid M et al., PLoS One 2011, retracted 31 Dec 2018: Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells (notice)
  2. Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review). Oncology Reports 2021.
    • cites Feng SD et al., Onco Targets Ther 2017, retracted 9 Mar 2020: Simultaneous overexpression of miR-126 and miR-34a induces a superior antitumor efficacy in pancreatic adenocarcinoma (notice)
  3. Biological functions and potential mechanisms of miR‑143‑3p in cancers (Review). Oncology Reports 2024.
    • cites Ding X et al., Onco Targets Ther 2019, retracted 6 Apr 2023: MicroRNA-143-3p suppresses tumorigenesis by targeting catenin-δ1 in colorectal cancer (notice)
    • cites Sun F et al., Onco Targets Ther 2020, retracted 11 Sep 2023: Long Noncoding RNA PVT1 Promotes Prostate Cancer Metastasis by Increasing NOP2 Expression via Targeting Tumor Suppressor MicroRNAs (notice)
  4. Epigenetic regulation of mRNA mediates the phenotypic plasticity of cancer cells during metastasis and therapeutic resistance (Review). Oncology Reports 2024.
    • cites Cheng C et al., Mol Ther Nucleic Acids 2021, retracted 5 Oct 2023: METTL3-mediated m6A modification of ZBTB4 mRNA is involved in the smoking-induced EMT in cancer of the lung (notice) Received 8 Sep 2023, retraction notice 5 Oct 2023, published online 19 Dec 2023.
  5. NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia. Oncology Reports 2023.
    • cites Sun X et al., J Healthc Eng 2022, retracted 28 Dec 2022: MiR-483 Promotes Colorectal Cancer Cell Biological Progression by Directly Targeting NDRG2 through Regulation of the PI3K/AKT Signaling Pathway and Epithelial-to-Mesenchymal Transition (notice) Received 3 Nov 2022, retraction notice 28 Dec 2022, published online 16 Jun 2023.
Oncotarget Journal · 142 of 388 citations cited as support (36.6%); we read 9 again and 4 held up. Written to 1 Nov 2026.

Reply (4 Nov 2026): The journal’s Scientific Integrity Office said it is reviewing the information and will look into these citations. In their words: We are reviewing the information provided and will look into these citations.

  1. Transcriptional repression of FOXO1 by KLF4 contributes to glioma progression. Oncotarget 2016.
    • cites Bois PR et al., J Cell Biol 2005, retracted 7 May 2007: FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma (notice)
  2. Downregulated miR-31 level associates with poor prognosis of gastric cancer and its restoration suppresses tumor cell malignant phenotypes by inhibiting E2F2. Oncotarget 2016.
    • cites Valastyan S et al., Cancer Res 2010, retracted 30 Jun 2015: Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis (notice)
  3. Epithelial-to-mesenchymal transition in the development of endometriosis. Oncotarget 2017.
    • cites Jia J et al., PLoS One 2012, retracted 10 Sep 2014: Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma (notice)
  4. STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget 2016.
    • cites Kumar MS et al., Nature 2014, retracted 10 Jun 2015: HMGA2 functions as a competing endogenous RNA to promote lung cancer progression (notice)
Agnieszka Rak Author · 3 citations in 3 of their papers held up on a second reading. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. Visfatin impact on the proteome of porcine luteal cells during implantation. Scientific Reports 2024.
    • cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin (notice)
  2. Visfatin (NAMPT) affects global gene expression in porcine anterior pituitary cells during the mid-luteal phase of the oestrous cycle. Journal of Animal Science and Biotechnology 2024.
    • cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin (notice)
  3. Visfatin exerts an anti-proliferative and pro-apoptotic effect in the human placenta cells. Biology of Reproduction 2025.
    • cites Fukuhara A et al., Science 2005, retracted 26 Oct 2007: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin (notice)
Ali Zarrabi Author · 6 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Life 2020.
    • cites Malhotra D et al., Am J Respir Crit Care Med 2009, retracted 1 Feb 2016: Heightened endoplasmic reticulum stress in the lungs of patients with chronic obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity (notice)
  2. The long and short non-coding RNAs modulating EZH2 signaling in cancer. Journal of Hematology & Oncology 2022.
    • cites Zhu F et al., J Cell Biochem 2018, retracted 9 Jun 2021: LncRNA AWPPH inhibits SMAD4 via EZH2 to regulate bladder cancer progression (notice)
    • cites Pan MZ et al., Eur Rev Med Pharmacol Sci 2019, retracted 10 Mar 2021: MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2 (notice)
    • cites Zheng W et al., Cancer Manag Res 2020, retracted 18 Sep 2021: microRNA-26a Directly Targeting MMP14 and MMP16 Inhibits the Cancer Cell Proliferation, Migration and Invasion in Cutaneous Squamous Cell Carcinoma (notice)
  3. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. Journal of Hematology & Oncology 2022.
    • cites Wu J et al., Hepatology 2021, retracted 1 Dec 2021: M2 Macrophage-Derived Exosomes Facilitate HCC Metastasis by Transferring α(M) β(2) Integrin to Tumor Cells (notice)
  4. Lipid-Based Delivery Systems for Flavonoids and Flavonolignans: Liposomes, Nanoemulsions, and Solid Lipid Nanoparticles. Pharmaceutics 2023.
    • cites Li P et al., Int J Nanomedicine 2020, retracted 4 Aug 2022: Apigenin-Loaded Solid Lipid Nanoparticle Attenuates Diabetic Nephropathy Induced by Streptozotocin Nicotinamide Through Nrf2/HO-1/NF-kB Signalling Pathway (notice)
Learn-Han Lee Author · 1 citation in 1 of their papers held up on a second reading. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. Targeting mTOR as a Cancer Therapy: Recent Advances in Natural Bioactive Compounds and Immunotherapy. Cancers 2022.
    • cites Pedrero JM et al., Int J Cancer 2005, retracted 6 May 2019: Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma (notice) The reference list marks it retracted.
Mariusz Jaremko Author · 12 citations in 5 of their papers held up on a second reading. Written to 1 Nov 2026.

Reply (1 Nov 2026): Dr Jaremko objects to being listed and to having his replies quoted or summarised. He says the papers are joint work by several authors and asks that any paper wrongly attributed to him be removed. He says he may take legal action. In their words: I reserve all my rights to pursue appropriate legal remedies, including proceedings before the competent courts and, where applicable, a complaint to the relevant data protection supervisory authority.

  1. Adjuvant Novel Nanocarrier-Based Targeted Therapy for Lung Cancer. Molecules 2024.
    • cites Akbarzadeh A et al., J Nanobiotechnology 2012, retracted 19 Jan 2019: Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line (notice)
    • cites Wang JY et al., ACS Omega 2020, retracted 19 Jul 2021: Nanostructured Lipid Carriers Delivering Sorafenib to Enhance Immunotherapy Induced by Doxorubicin for Effective Esophagus Cancer Therapy (notice)
  2. Fungal Endophytes: Microfactories of Novel Bioactive Compounds with Therapeutic Interventions; A Comprehensive Review on the Biotechnological Developments in the Field of Fungal Endophytic Biology over the Last Decade. Biomolecules 2023.
    • cites Mishra VK et al., PLoS One 2017, retracted 26 May 2022: Determination and production of antimicrobial compounds by Aspergillus clavatonanicus strain MJ31, an endophytic fungus from Mirabilis jalapa L. using UPLC-ESI-MS/MS and TD-GC-MS analysis (notice)
  3. Novel Copper Oxide Bio-Nanocrystals to Target Outer Membrane Lectin of Vancomycin-Resistant Enterococcus faecium (VREfm): In Silico, Bioavailability, Antimicrobial, and Anticancer Potential. Molecules 2022.
    • cites Maqbool Q et al., Front Pharmacol 2018, retracted 7 Feb 2019: CuO and CeO2 Nanostructures Green Synthesized Using Olive Leaf Extract Inhibits the Growth of Highly Virulent Multidrug Resistant Bacteria (notice)
  4. Unveiling Novel Drug Targets and Emerging Therapies for Rheumatoid Arthritis: A Comprehensive Review. ACS Pharmacology & Translational Science 2024.
    • cites Qu Y et al., J Cell Physiol 2019, retracted 20 Jul 2021: Downregulated microRNA-135a ameliorates rheumatoid arthritis by inactivation of the phosphatidylinositol 3-kinase/AKT signaling pathway via phosphatidylinositol 3-kinase regulatory subunit 2 (notice)
    • cites Li D et al., Biosci Rep 2019, retracted 28 Jul 2021: MiRNA-506 inhibits rheumatoid arthritis fibroblast-like synoviocytes proliferation and induces apoptosis by targetting TLR4 (notice)
    • cites Qiang J et al., Biosci Rep 2019, retracted 1 Sep 2020: Down-regulation of microRNA-142-3p inhibits the aggressive phenotypes of rheumatoid arthritis fibroblast-like synoviocytes through inhibiting nuclear factor-κB signaling (notice)
    • cites Wei Q et al., Biosci Rep 2020, retracted 4 Aug 2020: MicroRNA-101-3p inhibits fibroblast-like synoviocyte proliferation and inflammation in rheumatoid arthritis by targeting PTGS2 (notice)
    • cites Hu X et al., Mol Ther Nucleic Acids 2020, retracted 13 May 2022: Silencing of Long Non-coding RNA HOTTIP Reduces Inflammation in Rheumatoid Arthritis by Demethylation of SFRP1 (notice)
    • cites Huang Y et al., Cell Cycle 2020, retracted 21 Jun 2022: Up-regulated microRNA-411 or declined RIPK1 inhibits proliferation and promotes apoptosis of synoviocytes in rheumatoid arthritis mice via decreased NF-κB pathway (notice)
    • cites Wang ZQ et al., J Clin Lab Anal 2020, retracted 6 Dec 2021: Long non-coding RNA XIST binding to let-7c-5p contributes to rheumatoid arthritis through its effects on proliferation and differentiation of osteoblasts via regulation of STAT3 (notice)
  5. Deciphering the therapeutic potential of trimetazidine in rheumatoid arthritis via targeting mi-RNA128a, TLR4 signaling pathway, and adenosine-induced FADD-microvesicular shedding: In vivo and in silico study. Frontiers in Pharmacology 2024.
    • cites Zhang X et al., Contrast Media Mol Imaging 2022, retracted 19 Jul 2023: Investigation on the Inhibitory Effect of Methotrexate on Rheumatoid Synovitis via the TLR4-NF-κB Pathway in a Rat Model (notice)
Sachin Kumar Singh Author · 3 citations in 3 of their papers held up on a second reading. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. Implications of reactive oxygen species in lung cancer and exploiting it for therapeutic interventions. Medical Oncology 2022.
    • cites Raj L et al., Nature 2011, retracted 25 Jul 2018: Selective killing of cancer cells by a small molecule targeting the stress response to ROS (notice)
  2. Unlocking the power of nanomedicine: the future of nutraceuticals in oncology treatment. Frontiers in Nutrition 2023.
    • cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021: Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade (notice) The reference list marks it retracted.
  3. Autophagy-associated non-coding RNAs: Unraveling their impact on Parkinson's disease pathogenesis. CNS Neuroscience & Therapeutics 2024.
    • cites Dong X et al., Dis Markers 2022, retracted 2 Aug 2023: Inhibition of miR-421 Preserves Mitochondrial Function and Protects against Parkinson's Disease Pathogenesis via Pink1/Parkin-Dependent Mitophagy (notice)
Samy Selim Author · 5 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies. Food Science & Nutrition 2025.
    • cites Patil SP et al., Neuropharmacology 2014, retracted 9 Nov 2021: Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice (notice)
  2. Isoflavones: Promising Natural Agent for Cancer Prevention and Treatment. Food Science & Nutrition 2025.
    • cites Xiao P et al., Oncol Lett 2017, retracted 12 Apr 2021: Biochanin A induces anticancer effects in SK-Mel-28 human malignant melanoma cells via induction of apoptosis, inhibition of cell invasion and modulation of NF-kB and MAPK signaling pathways (notice) The reference list marks it retracted.
    • cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021: Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade (notice) The reference list marks it retracted.
  3. Recent Perspectives on Anticancer Potential of Coumarin Against Different Human Malignancies: An Updated Review. Food Science & Nutrition 2025.
    • cites Dong L et al., Oncol Rep 2018, retracted 26 Apr 2021: In vitro and in vivo anticancer effects of marmesin in U937 human leukemia cells are mediated via mitochondrial-mediated apoptosis, cell cycle arrest, and inhibition of cancer cell migration (notice)
  4. Novel Copper Oxide Bio-Nanocrystals to Target Outer Membrane Lectin of Vancomycin-Resistant Enterococcus faecium (VREfm): In Silico, Bioavailability, Antimicrobial, and Anticancer Potential. Molecules 2022.
    • cites Maqbool Q et al., Front Pharmacol 2018, retracted 7 Feb 2019: CuO and CeO2 Nanostructures Green Synthesized Using Olive Leaf Extract Inhibits the Growth of Highly Virulent Multidrug Resistant Bacteria (notice)
Shafiul Haque Author · 7 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.

Reply: none received by 8 Nov 2026.

  1. Serum Cytokine Profile in Patients with Chronic Rhinosinusitis with Nasal Polyposis Infected by Aspergillus flavus. Annals of Laboratory Medicine 2018.
    • cites Radhakrishnan S et al., J Immunol 2008, retracted 1 Jun 2010: Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo (notice)
  2. Roles of HOTAIR Long Non-coding RNA in Gliomas and Other CNS Disorders. Cellular and Molecular Neurobiology 2024.
    • cites Sa L et al., Front Mol Neurosci 2017, retracted 2 May 2023: The Role of HOTAIR/miR-148b-3p/USF1 on Regulating the Permeability of BTB (notice)
    • cites Zhao W et al., Cancer Med 2018, retracted 15 Dec 2023: LncRNA HOTAIR influences cell growth, migration, invasion, and apoptosis via the miR-20a-5p/HMGA2 axis in breast cancer (notice) Received 15 Jun 2023, retraction notice 15 Dec 2023, published online 16 Feb 2024.
    • cites Wang Z et al., Comput Math Methods Med 2022, retracted 6 Dec 2023: lncRNA HOTAIR Inhibition by Regulating HMGB1/ROS/NF-κB Signal Pathway Promotes the Recovery of Spinal Cord Function (notice) Received 15 Jun 2023, retraction notice 6 Dec 2023, published online 16 Feb 2024.
  3. The multifaceted functions of long non-coding RNA HOTAIR in neuropathologies and its potential as a prognostic marker and therapeutic biotarget. Expert Reviews in Molecular Medicine 2024.
    • cites Sa L et al., Front Mol Neurosci 2017, retracted 2 May 2023: The Role of HOTAIR/miR-148b-3p/USF1 on Regulating the Permeability of BTB (notice)
    • cites Wang Z et al., Comput Math Methods Med 2022, retracted 6 Dec 2023: lncRNA HOTAIR Inhibition by Regulating HMGB1/ROS/NF-κB Signal Pathway Promotes the Recovery of Spinal Cord Function (notice) Received 5 Sep 2023, retraction notice 6 Dec 2023, published online 29 Apr 2024.
  4. Gut Microbiota-Assisted Synthesis, Cellular Interactions and Synergistic Perspectives of Equol as a Potent Anticancer Isoflavone. Pharmaceuticals 2022.
    • cites Hua F et al., Int J Mol Med 2018, retracted 7 Apr 2021: Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade (notice)
Zodwa Dlamini Author · 5 citations in 4 of their papers held up on a second reading. Written to 30 Oct 2026.

Reply (6 Nov 2026): Professor Dlamini confirmed the five citations across the four reviews, said the journals had not flagged the retractions at any stage, and noted that the Genes 2022 review was submitted on 13 December 2021, a week before the cited study was retracted. In their words: the absence of such acknowledgement should not be interpreted as evidence that the authors knowingly cited retracted research

  1. Reports of Plant-Derived Nanoparticles for Prostate Cancer Therapy. Plants 2023.
    • cites Pulukuri SM et al., J Biol Chem 2005, retracted 11 Sep 2020: RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo (notice)
  2. The Role of MicroRNAs in Kidney Disease. Non-Coding RNA 2015.
    • cites Gupta A et al., PLoS One 2011, retracted 29 Aug 2012: Comparative expression profile of miRNA and mRNA in primary peripheral blood mononuclear cells infected with human immunodeficiency virus (HIV-1) (notice)
  3. MicroRNA Interrelated Epithelial Mesenchymal Transition (EMT) in Glioblastoma. Genes 2022.
    • cites Zhang C et al., J Exp Clin Cancer Res 2017, retracted 20 Dec 2021: TGF-β2 initiates autophagy via Smad and non-Smad pathway to promote glioma cells' invasion (notice) Received 13 Dec 2021, retraction notice 20 Dec 2021, published online 27 Jan 2022.
  4. Exosomal long non-coding RNAs in cancer: Interplay, modulation, and therapeutic avenues. Non-coding RNA Research 2024.
    • cites Zhang W et al., Int J Oncol 2018, retracted 21 Nov 2022: Exosome-mediated transfer of lncRNA RP11‑838N2.4 promotes erlotinib resistance in non-small cell lung cancer (notice)
    • cites Kang M et al., J Exp Clin Cancer Res 2018, retracted 6 Apr 2023: Exosome-mediated transfer of lncRNA PART1 induces gefitinib resistance in esophageal squamous cell carcinoma via functioning as a competing endogenous RNA (notice)
How we checked

Counted by the census, then read again.

How these lists were checked

Papers
Every citation counted as support was read again in full (23 Oct 2026) for each listed paper and each paper near the last place, 21 papers in all. For the 8 nearest the last place, each citation was read twice, independently, and a third reading settled any disagreement. The 2 papers left off after reading were judged on their second reading, not read in full.
Journals
A random sample of 7 to 10 support citations per journal was read again, not every citation.
Authors
Every support citation in every listed author's papers was read again (153 different citations; 217 author items, because the 3 authors who share papers wrote most of them together, so their counts overlap).

All of these are AI readings.

Everyone named was written to before publication, sent the evidence and asked to tell us if a reading is wrong. Replies received by the date in each letter (28 October, 30 October) (5 on the page so far; all replies) are summarised and quoted beside their entries; the 2 statements written for publication are printed as written.

  • AI readings.Each label is our reading of a published passage by the method on this page, and each paper and author item links to its passages so you can judge it yourself. The counts come from the Phase 2 census: three AI models read every citing passage. Each list was then checked again, as set out in the box at the top; those are AI readings too. Everyone named was sent the evidence and asked to tell us if a reading is wrong; where one is, we correct the entry and say so beside it.
  • Dates and reasons from the notice.Each retraction date and reason on the lists comes from the journal's retraction notice, not from a database. Where we have not yet read a notice, we say so instead of giving a reason. Corrections made after the data was built are listed, with their sources, in list_corrections.json.
  • What each paper reached.For every paper the census found citing a listed paper as support after its retraction, we read its Europe PMC record on 29 October 2026: its publication type (review, systematic review, trial) and the grants it acknowledges. "In turn" counts the distinct later papers that cite any of those papers, for any reason, with the systematic reviews, trials and guidelines among them as Europe PMC types them; it measures reach, not harm. Registered trials are ClinicalTrials.gov records first submitted after the retraction that list the retracted paper among their references. Totals are in reach.json.
  • Followed by reading.For a paper we could follow, we took one of its most-cited supporting papers that repeats the retracted claim, then searched Europe PMC for later papers that cite it and mention the same topic. In every one we could read in full (among the first 100 search results), we found the sentence that cites it and judged by hand whether that sentence repeats the retracted claim. A search word can match a sentence that says the opposite, so no count rests on the word alone.
  • Only citations made after the retraction.A citation counts if the citing paper came out after the retraction. That means it first went online on or after the earliest date we hold for the retraction (the notice's PubMed, Crossref or Retraction Watch date), compared to the day; papers submitted or accepted before the notice carry their timeline. Until 9 Nov 2026 we compared calendar years except where we had checked dates one by one; citations by papers that went online before the retraction are now left out, each listed in list_corrections.json.
  • Only retractions about the results.Citations of a paper are left out when its retraction notice gives only reasons that do not touch the results, such as reused text, a duplicate of a result that stays published, authorship, ethics paperwork, copyright or a software licence, or a wrong journal; the census already leaves out paperwork retractions the same way. We apply this where we have read the notice. A notice that gives no reason, or an unclear one, still counts and is marked "reason unclear". They are not hidden: 289 later citations cite 20 such papers as support, from 289 citing papers. The papers · every citation, labelled with the reason.
  • Only confirmed retractions.The lists use only papers PubMed links to a retraction notice: 45,467 judged citations to 11,649 retracted papers. Papers replaced by a corrected version, and paperwork retractions that find no fault in the science, are left out.
  • Authors by ORCID only.Authors are matched by their ORCID iD, so two people with the same name are never merged. Authors without an ORCID iD in Europe PMC cannot be listed, so this is not every author.
  • What the second reading found.Of 599 different citations the census called support and we read again, 511 (85.3%) held up after every reading. 58 only mentioned the paper in passing, 7 flagged it as retracted or unreliable, and 23 were about something else, most often because the reference pointed at the wrong paper. These citations come from the top of each list, so they are not a rate for the whole census. The file lists the 454 that belong to entries on this page; the rest belong to places below the cut and are kept back. Some papers were cited only for a tool or method that still works; those are left off, with the reason shown.
  • Open-access papers only.The census reads papers whose full text is open in Europe PMC. Journals that publish everything open access are counted in full, others only in part, so the counts favour large open-access journals.
  • Check it yourself.Each list as a CSV: papers · journals by count · journals by share · authors. every author item, with the notice's reason class and any timeline. Every citation read again, with its verdict and a note. Every reply from the people named, as summarised. What each column means.
  • The full tables.All 11,649 retracted papers and all 3,807 citing journals. They are ranked by count with the corrections in list_corrections.json applied: 290 papers' counts differ from the census labels alone, and the file gives both. Only the listed entries and the papers near the last place were read again. All papers · all journals · PubMed retraction status of every paper. Their reason column is grouped from Retraction Watch codes, not the notice's wording.
  • Corrections.If you are named and think an entry is wrong, write to SaneCite at letters@sanecite.com, with the citing paper's PMC number if you have it. We reply within two working days and decide within seven days. A correction is made beside the entry, dated, and logged in list_corrections.json. You can also ask us to take an entry down: it comes off when the evidence shows a reading is wrong or a citation is out of scope, the same rule for everyone, and if it stays we tell you why.
Named people and your data

What we hold about the people named, and why.

  • Who is responsible.SaneCite, an independent research project in Georgia, USA. To reach us, write to SaneCite at letters@sanecite.com.
  • What we use.Names, ORCID iDs and publication records: titles, journals, dates, reference lists and the passages that cite retracted work. And the replies people send us.
  • Where it comes from.Public records: Europe PMC (with the ORCID iDs it holds), PubMed, the Retraction Watch database and the journals' own retraction notices.
  • Why, and on what basis.Research in the public interest on how the published record handles retracted work, and publishing its results. Where UK or European data protection law applies, we rely on legitimate interests in research and free expression, and on the exemptions those laws give to academic and journalistic work. Entries come from whole-set counts, never picked by hand.
  • How entries are made.By AI readings of the citing passages, by the method on this page, with a right of reply for the people named before publication.
  • What we print from a reply.A summary in our words, one short quote, and any statement written for publication, the same for everyone. From 2 November 2026, a reply that threatens legal action or a complaint to a regulator is printed in full beside the entry. We never print email addresses, phone numbers or details about other people. Any other full reply is kept privately and shared only when needed, with a journal, a fiscal sponsor or a lawyer.
  • How long.Published entries stay as part of the research record, with every correction dated. Private correspondence is kept while the entry is published and for two years after.
  • Your rights.You can ask us to correct your entry, to tell you what we hold about you, to restrict or stop a use, or to delete what we hold: write to SaneCite at letters@sanecite.com. We reply within two working days and decide within one month. Where we keep a published entry because the research record needs it, we tell you why. You can also complain to your data protection authority (in the UK, the Information Commissioner's Office).